Skip to main content
. 2024 Sep 15;14(9):4523–4536. doi: 10.62347/DVXL1377

Figure 5.

Figure 5

Cytokine analysis in KRAS G12D vs KRAS G13D and G12V treated with 5-FU and MRTX1133. Effects are independent of KRAS subtypes with no effect on wild-type (WT). Increase in IL-18 after combination therapy was observed regardless of KRAS mutation status, also a decrease in IL-8, MICA, VEGF, Angiopoietin 2 and TGF-Alpha was found at 48-hour time point.